{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:11:35Z","timestamp":1767165095790,"version":"build-2238731810"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T00:00:00Z","timestamp":1139875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of tramadol in patients with idiopathic detrusor overactivity (IDO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 76 patients 18\u2003years or older with IDO were randomly assigned to receive 100\u2003mg tramadol sustained release (group 1,\n                      <jats:italic>n<\/jats:italic>\n                      \u2003=\u200338) or placebo (group 2,\n                      <jats:italic>n<\/jats:italic>\n                      \u2003=\u200338) every 12\u2003h for 12\u2003weeks. Clinical evaluation was performed at baseline and every 2\u2003weeks during treatment. All patients underwent urodynamics and ice water test at baseline and 12\u2010week treatment. Main outcome measures were number of voids per 24\u2003h, urine volume per void and episodes of urge incontinence per 24\u2003h on a frequency volume chart and detailed recording of adverse effect.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 12\u2003weeks of treatment mean number of voids per 24\u2003h \u00b1 SD decreased from 9.3\u2003\u00b1\u20033.2 to 5.1\u2003\u00b1\u20032.1 (\n                      <jats:italic>P\u2003<\/jats:italic>\n                      &lt;\u20030.001\n                      <jats:italic>vs.<\/jats:italic>\n                      placebo) [95% confidence interval (CI) \u22125.1\u2010\u22120.4]. At that time mean urine volume per void increased from 158\u2003\u00b1\u200332 to 198\u2003\u00b1\u200376\u2003ml (\n                      <jats:italic>P\u2003<\/jats:italic>\n                      &lt;\u20030.001\n                      <jats:italic>vs.<\/jats:italic>\n                      placebo) (95% CI 8\u201022), while mean number of incontinence episodes per 24\u2003h decreased from 3.2\u2003\u00b1\u20033.3 to 1.6\u2003\u00b1\u20032.8 (\n                      <jats:italic>P\u2003<\/jats:italic>\n                      &lt;\u20030.001\n                      <jats:italic>vs.<\/jats:italic>\n                      placebo) (95% CI \u22122\u20100.3). Tramadol induced significant improvements in urodynamic parameters. More adverse effects were associated with tramadol treatment than with placebo (\n                      <jats:italic>P\u2003<\/jats:italic>\n                      &lt;\u20030.05). The main adverse event with tramadol was nausea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with non\u2010neurogenic IDO tramadol provided beneficial clinical and urodynamic results. Further studies are required to draw final conclusions on the efficacy of this drug in IDO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1365-2125.2006.02597.x","type":"journal-article","created":{"date-parts":[[2006,2,14]],"date-time":"2006-02-14T05:07:24Z","timestamp":1139893644000},"page":"456-463","source":"Crossref","is-referenced-by-count":33,"title":["<i>Retracted:<\/i>\n                    Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double\u2010blind, placebo\u2010controlled, randomized study"],"prefix":"10.1111","volume":"61","author":[{"given":"M. R.","family":"Safarinejad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Y.","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.spv.0000128875.25989.80"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38459-8"},{"key":"e_1_2_5_7_2","first-page":"432","article-title":"Anticholinergic therapy: the need for continued surveillance","volume":"13","author":"Kelleher CJ","year":"1994","journal-title":"Neurourol Urodynam"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000142121.24052.25"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aeg079"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(90)90105-R"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64683-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63020-9"},{"key":"e_1_2_5_13_2","first-page":"339","article-title":"Intravesical capsaicin for neurogenic bladder dysfunction","volume":"16","author":"Fowler CJ","year":"1992","journal-title":"Lancet"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000081652.31524.27"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90491-2"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200204000-00024"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200211000-00031"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00004"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000062528.54550.65"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66825-3"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(94)00685-Z"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2004.10.020"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I"},{"key":"e_1_2_5_24_2","first-page":"49","volume-title":"The Design and Analysis of Clinical Experiments.","author":"Fleiss J.","year":"1986"},{"key":"e_1_2_5_25_2","first-page":"175","article-title":"Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion","volume":"37","author":"Lintz W","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_5_26_2","first-page":"1932","article-title":"]","volume":"31","author":"Erlacin S","year":"1981","journal-title":"Arzneimittel Fortramadol Schung"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00717.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700532-00007"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(87)90218-1"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01634-X"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(03)00353-1"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705297"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(82)90154-X"}],"updated-by":[{"DOI":"10.1111\/bcp.12304","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"record-id":"1407"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2006.02597.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2006.02597.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:51:52Z","timestamp":1697413912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2006.02597.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,14]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1365-2125.2006.02597.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02597.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,14]]}}}